Myology research highlights

SMA is currently experiencing a therapeutic revolution, with more and more new molecules on the market or about to be approved. This crippling neuromuscular disease affects several thousand patients in Europe. Many of them are active in European patient associations, most of which are affiliated with SMA-Europe.  This associative alliance reports, in an article published … [Read more]

A team from Nantes University Hospital is launching a retrospective study, led by Prof. Sandra Mercier, geneticist, to describe the forms of severe heart failure in women with dystrophinopathy. Less than 10% of these women suffer from more or less severe heart disease.  The study will allow a more detailed description of the cardiac involvement, … [Read more]

Oculopharyngeal muscular dystrophy (or OPMD) is a relatively rare type of muscular dystrophy that tends to affect and older population. This condition is transmitted in an autosomal dominant manner, and results in the gradual development, from 50 years of age, of the bilateral drooping of the eyelids and difficulty swallowing, and also the appearance of … [Read more]

After obtaining positive results on the motor development of 15 infants with type I SMA, aged less than 6 months and symptomatic during the first gene therapy trial lasting two years (START study), Zolgensma (onasemnogene abeparvovec) will be evaluated over the next 15 years (START long-term follow-up study).  The results published after five years of … [Read more]

SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) developed in Duchenne muscular dystrophy (DMD) by Sarepta Therapeutics is a gene therapy product combining a micro-dystrophin gene and an adeno-associated virus  (AAV). Sarepta announced in a press release dated May 18, 2021, the first results of the US ENDEAVOR trial of SRP-9001 in its commercial form in 20 participants, boys with DMD … [Read more]

The question of neonatal screening for SMA does rise more and more since the marketing of three disease-modifying therapies, Spinraza®, Zolgensma® and Evrysdi®, which efficacy is optimal if they are initiated as early as possible, pre-symptomatically. But where is newborn screening for SMA in the world today?   The results of a large survey of … [Read more]

On the initiative of FSHD Europe association, in which the AFM-Telethon is involved, a European network of clinical trials in FSH has just been created with the aim of connecting European clinicians involved in FSH and to facilitate the setting up of future clinical trials, to make future treatments more accessible, etc. This network is … [Read more]

Becker muscular dystrophy (BMD) is the result of a partial dystrophin deficiency. Approximately 40% of adults with BMD present dilated cardiomyopathy, including 15% of under 20-year-olds and 55% of over 40-year-olds. International cardiological guidelines recommend the prescription of angiotensin converting enzyme (ACE) inhibitors when the left ventricular ejection fraction (LVEF) drops below 40%. A retrospective … [Read more]

In the field of innovative therapies for neuromuscular diseases, having access to a model, whether cell or animal, for a given disease is a major benefit. These models make it possible to test several therapeutic hypotheses on a large scale, and are usually a prerequisite to starting human trials. Since animal models are rare in … [Read more]

Of the many forms of spinal muscular atrophy (SMA), the form causing predominately proximal muscle deficit and associated with a lack of the SMN protein is by far the most common form in children. This condition is diagnosed by identifying a homozygous deletion in the SMN1 gene, found in 98% of cases. The prognosis can, … [Read more]